NCT02033239 - A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

Faster-acting insulin aspart

Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).

DRUG

insulin aspart

Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss